Gilead Sciences | GILD - Ordinary Share Capital


Gilead Sciences reported $1.24B in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 608K Jun/2026
Agios Pharmaceuticals USD 59.6M 264K Jun/2026
ALKERMES USD 168.03M 489K Sep/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
Amgen USD 541M 0 Sep/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.68M 141K Sep/2026
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
Glaxosmithkline GBP 2.02B 2.03B Sep/2026
Incyte USD 200.98M 1.03M Jun/2026
J&J USD 2.41B 1.64M Jun/2026
Merck USD 2.47B 1.05M Jun/2026
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Novartis USD 1.89B 12.09M Sep/2026
Pfizer USD 5.7B 1000K Sep/2026
PTC Therapeutics USD 83.33M 445K Jun/2026
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sanofi EUR 1.2B 0 Sep/2026
Sarepta Therapeutics USD 107.23M 1.61M Sep/2026
United Therapeutics USD 42.38M 295K Sep/2026
Vertex Pharmaceuticals USD 253.5M 200K Sep/2026